IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLC

Miguel García-Pardo; Laura Mezquita

doi:10.1016/j.medj.2023.10.002

IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLC

Med. 2023 Nov 10;4(11):745-748. doi: 10.1016/j.medj.2023.10.002.

Authors

Miguel García-Pardo¹, Laura Mezquita²

Affiliations

¹ Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
² Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; Laboratory of Translational Genomic and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain. Electronic address: lmezquita@clinic.cat.

PMID: 37951206
DOI: 10.1016/j.medj.2023.10.002

Abstract

First-line therapy for advanced non-small cell lung cancer (NSCLC) involves immunotherapy with or without platinum-based chemotherapy; however, not all patients are fit enough. In the IPSOS trial, atezolizumab monotherapy demonstrated a clinical benefit in platinum-ineligible patients with advanced NSCLC, redefining first-line immunotherapy, and breaking barriers for unfit population in NSCLC.

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Clinical Trials as Topic
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Platinum / therapeutic use

Substances

Platinum